Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA: 603392)
China
· Delayed Price · Currency is CNY 68.47
-0.75 (-1.08%)
Sep 6, 2024, 3:00 PM CST
Beijing Wantai Biological Pharmacy Enterprise Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | -194.2 | 1,248 | 4,736 | 2,021 | 677 | 208.86 | Upgrade
|
| Depreciation & Amortization | 248.17 | 224.21 | 151.9 | 105.28 | 84.47 | 80.51 | Upgrade
|
| Other Amortization | -81.11 | 31.41 | 6.63 | 5.03 | 2.07 | 1.8 | Upgrade
|
| Loss (Gain) From Sale of Assets | -0.42 | -0.22 | -0.06 | 0.72 | -0.42 | 1.37 | Upgrade
|
| Asset Writedown & Restructuring Costs | 259.87 | 260.46 | 2.8 | 0.25 | - | 0.1 | Upgrade
|
| Loss (Gain) From Sale of Investments | -152.12 | -123.56 | -46.09 | -11.25 | -13.6 | -13.88 | Upgrade
|
| Provision & Write-off of Bad Debts | -39.53 | -23.27 | 90.61 | 83.95 | 24.07 | 4.25 | Upgrade
|
| Other Operating Activities | 190.83 | 199.37 | 129.61 | 96.86 | 46.91 | 13.41 | Upgrade
|
| Change in Accounts Receivable | 2,118 | 984.81 | -1,778 | -1,707 | -487.31 | -81.75 | Upgrade
|
| Change in Inventory | 70.53 | -218.34 | -296.47 | -222.97 | -190.68 | -49.65 | Upgrade
|
| Change in Accounts Payable | -811.79 | -935.62 | 1,116 | 1,322 | 287.39 | 137.31 | Upgrade
|
| Change in Other Net Operating Assets | - | - | - | -0 | - | - | Upgrade
|
| Operating Cash Flow | 1,500 | 1,538 | 4,133 | 1,682 | 468.21 | 272.68 | Upgrade
|
| Operating Cash Flow Growth | -41.81% | -62.79% | 145.70% | 259.23% | 71.71% | 30.90% | Upgrade
|
| Capital Expenditures | -1,008 | -1,160 | -929.91 | -1,048 | -390.44 | -162 | Upgrade
|
| Sale of Property, Plant & Equipment | 1.89 | 0.72 | 0.89 | 8.19 | 2.73 | 0.68 | Upgrade
|
| Cash Acquisitions | -0.71 | -0.71 | - | - | - | - | Upgrade
|
| Investment in Securities | -819.37 | -960.3 | -2,589 | 14.39 | 86.52 | -48.2 | Upgrade
|
| Other Investing Activities | 104.44 | 66.23 | 3.9 | 11.11 | 5.78 | 11.16 | Upgrade
|
| Investing Cash Flow | -1,723 | -2,054 | -3,514 | -1,014 | -295.4 | -198.37 | Upgrade
|
| Long-Term Debt Issued | - | 186.44 | 351.6 | 240.35 | 90.37 | - | Upgrade
|
| Total Debt Issued | 171.31 | 186.44 | 351.6 | 240.35 | 90.37 | - | Upgrade
|
| Long-Term Debt Repaid | - | -170.57 | -352.46 | -92.06 | -33.77 | - | Upgrade
|
| Net Debt Issued (Repaid) | -46.79 | 15.87 | -0.86 | 148.29 | 56.6 | - | Upgrade
|
| Issuance of Common Stock | 78.21 | 54 | 3,461 | 10 | 342.28 | - | Upgrade
|
| Repurchase of Common Stock | -66.39 | -15.65 | -200.17 | - | - | - | Upgrade
|
| Common Dividends Paid | -424.56 | -907.47 | -127.49 | -112.74 | -1.65 | -1.04 | Upgrade
|
| Other Financing Activities | -32.08 | -40 | -5.68 | 7.23 | -17.43 | -4.13 | Upgrade
|
| Financing Cash Flow | -491.61 | -893.26 | 3,127 | 52.79 | 379.79 | -5.18 | Upgrade
|
| Foreign Exchange Rate Adjustments | -2.2 | 7.62 | 26.26 | -8.75 | -9.01 | 0.22 | Upgrade
|
| Net Cash Flow | -716.68 | -1,402 | 3,772 | 711.88 | 543.59 | 69.35 | Upgrade
|
| Free Cash Flow | 492 | 378.15 | 3,203 | 634.16 | 77.77 | 110.68 | Upgrade
|
| Free Cash Flow Growth | -68.68% | -88.19% | 405.03% | 715.43% | -29.73% | - | Upgrade
|
| Free Cash Flow Margin | 18.13% | 6.86% | 28.63% | 11.03% | 3.30% | 9.35% | Upgrade
|
| Free Cash Flow Per Share | 0.40 | 0.30 | 2.56 | 0.52 | 0.07 | 0.10 | Upgrade
|
| Cash Income Tax Paid | 88.8 | 537.3 | 1,164 | 295.76 | 145.34 | 99.9 | Upgrade
|
| Levered Free Cash Flow | 409.48 | 54.72 | 1,738 | -4.04 | -218.2 | 65.28 | Upgrade
|
| Unlevered Free Cash Flow | 413.33 | 59.01 | 1,743 | -0.48 | -217.15 | 65.93 | Upgrade
|
| Change in Net Working Capital | -1,558 | -110.49 | 776 | 461.51 | 366.22 | -52.28 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.